REG - Videndum PLC - March Covenant Test Waived

VidendumAnnouncement

31/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250331:nRSe7946Ca&default-theme=true

RNS Number : 7946C  Videndum PLC  31 March 2025

 

31 March 2025

Videndum plc

March covenant test waived; Future covenants to be reset

 

Videndum plc (the "Company") confirms that the March 2025 covenant test has
been waived, and the Company expects to reset all future covenant tests ahead
of announcing its results for FY24 at the end of April 2025.

The work required to refinance the Revolving Credit Facility, set to expire in
August 2026, continues and our lending banks remain supportive of the Company.

 

Enquiries

FTI Consulting

Richard Mountain / Ben Fletcher

Telephone: 020 3272 1340

 

Videndum

Stephen Harris

Group Executive Chairman

Telephone: 020 8332 4602

 

A snapshot of Videndum plc

Videndum is a leading global provider of premium branded hardware products and
software solutions to the growing content creation market.

Videndum's customers include broadcasters, film studios, production and rental
companies, photographers, independent content creators, gamers, professional
musicians and enterprises. Our product portfolio includes camera supports,
video transmission systems and monitors, live streaming solutions, smartphone
accessories, robotic camera systems, prompters, LED lighting, mobile power,
carrying solutions, backgrounds, motion control, audio capture, and noise
reduction equipment.

We employ around 1,500 people across the world in 10 different countries.
Videndum plc is listed on the London Stock Exchange, ticker: VID.

More information can be found at: https://videndum.com/
(https://videndum.com/)

LEI number: 2138007H5DQ4X8YOCF14

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDPPUMGWUPAGGB